Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208548 | 0.90 | POLB (0.53) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL207969 | 0.89 | AURKA (0.46) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL210676 | 0.88 | AURKA (0.42) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL4754624 | 0.87 | PPARD (0.43) | ALDH1A1MAPTPOLBL3MBTL1NPBWR1 | |
| SCHEMBL209541 | 0.86 | DRD2 (0.50) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL209615 | 0.83 | MAPT (0.45) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL4757112 | 0.83 | DRD2 (0.38) | ALDH1A1MAPTPOLBL3MBTL1NPBWR1 | |
| SCHEMBL209883 | 0.81 | SIGMAR1 (0.46) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL207138 | 0.81 | NPC1 (0.45) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL17092831 | 0.81 | AURKA (0.45) | MEN1KMT2AALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515954-A | Salts and polymorphic forms of 6-chloro-7- (4- (4-chlorobenzyl) piperazin-1-yl) -2- (1,3-dimethyl-1H-pyrazol-4-yl) -3H-imidazo [4,5-B ] pyridine | 椭圆制药有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-2864328-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-12-06 | — | — | EP | disclosed |
| EP-2864328-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| EP-2864328-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | Cancer Research Technology Ltd (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | MEN1 471/4885KMT2A 384/4885ALDH1A1 3015/4885 |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | FLT3, AURKC, AURKA | MEN1 391/4885KMT2A 860/4885ALDH1A1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.